To read an article from the print magazine online, please enter the web code below, which can be found in the magazine under the article.

https://www.getdigital.de - Gadgets und mehr für Computerfreaks

A new era of lab working


“Gyros Protein Technologies is all about simplifying assays and analysis in biopharmaceutical development,” stresses Mark Vossenaar, Vice President European Sales. “In addition, time and sample reduction due to automated nanolitre scale immunoassays is a factor which has helped make our company one of the preferred partners in biotherapeutics.”

As tests developed on the Gyrolab platform are automated and only require very small quantities of fluids, they are ideal at early development stages when only small amounts can be provided.

“Gyrolab platforms run multiple samples in parallel, saving time, labour and precious samples and reagents,” explains Mr. Vossenaar. “The assay run time can be as much as ten times shorter compared to the traditional ELISA method. The automation does not only save time, it also minimizes the risk of errors.”

Due to the CD microstructures, only 20 to 200 nL are required for a test, which is beneficial when the samples being analyzed are rare, like synovial fluid or vitreous humor. Gyros Protein Technologies offers its customers from biopharmaceutics as well as from research institutes support in the use of its hard and software solutions.

“Our platforms are open, supporting individual adaptations by our customers,” Mr. Vossenaar points out. Gyros Protein Technologies organizes workshops and user group meetings in order to provide mutual exchange, and it also uses feedback from customers to adapt and develop new products accordingly.

Following last year’s merger between Gyros, the expert in microfluidics, systems development and immunoassays, and Protein Technologies, a provider of peptide synthesizers and reagents, the new company Gyros Protein Technologies has been able to increase its presence in the biopharmaceutical market.

“Our Gyrolab Systems have been developed to provide automation of immunoassays in every phase of drug development,” says Mr. Vossenaar. “The coming years will see new applications as well as increased automation and productivity, and the peptide synthesis business area will offer a new level of solutions. We are well prepared to tackle the future in biopharmaceuticals and speed up everyday lab procedures for the benefit of our customers.”

Bewerten Sie diesen Artikel